Compare ESTA & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESTA | MLYS |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2018 | 2023 |
| Metric | ESTA | MLYS |
|---|---|---|
| Price | $69.91 | $29.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $86.86 | $48.67 |
| AVG Volume (30 Days) | 322.1K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.67 | 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,208,000.00 | N/A |
| Revenue This Year | $28.05 | N/A |
| Revenue Next Year | $26.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 76.49 | N/A |
| 52 Week Low | $32.25 | $12.59 |
| 52 Week High | $83.31 | $47.65 |
| Indicator | ESTA | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 57.16 |
| Support Level | $68.75 | $26.85 |
| Resistance Level | $73.72 | $31.19 |
| Average True Range (ATR) | 3.36 | 1.65 |
| MACD | 0.55 | -0.15 |
| Stochastic Oscillator | 79.31 | 64.08 |
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.